Search

Background: The first International Consensus Conference for Advanced Breast Cancer (ABC1) took place 10 years ago in November 2011. The rationale was – and still is – to standardize treatment of advanced breast cancer (ABC) based on the available evidence and to ensure that worldwide all breast cancer patients receive adequate treatment and access to new therapies. Rationale for the Manuscript: The 6th International Consensus Conference for ABC (ABC6) took place from November 4 to 6, 2021 and was the first in a purely online format, due to the COVID-19 pandemic. In the present manuscript, a working group of German breast cancer experts comments on the voting results of the ABC6 panelists regarding their applicability for routine clinical practice in Germany. Method: The ABC6 votes mainly include modified or new statements. With regard to all statements not modified for the ABC6 consensus, the German experts refer to the published paper of the ABC5 consensus. The German experts base their comments on the current recommendations of the Breast Committee of the Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Mamma). Topics: ABC6 focused on new treatment options and their implications for clinical practice. Optimal therapy sequencing for example was one of the issues. To solve the challenge of a more individualized treatment, precision medicine is fundamental. Oligometastatic disease, brain metastases and adequate supportive and palliative care were also addressed. Of special interest was the treatment of inoperable locally advanced breast cancer, which was discussed as a separate topic. As in previous years, patient advocates from around the world were an integral part of the ABC6 conference and had a major input into the consensus. [ABSTRACT FROM AUTHOR]

The 5th International Consensus Conference for Advanced Breast Cancer (ABC5) took place on November 14–16, 2019, in Lisbon, Portugal. Its aim is to standardize the treatment of advanced breast cancer based on the available evidence and to ensure that all breast cancer patients worldwide receive adequate treatment and access to new therapies. This year, the conference focused on developments and study results in the treatment of patients with hormone receptor-positive/HER2-negative breast cancer as well as precision medicine. As in previous years, patient advocates from around the world were integrated into the ABC conference and had seats on the ABC consensus panel. In the present paper, a working group of German breast cancer experts comments on the results of the on-site ABC5 consensus votes by ABC panelists regarding their applicability for routine treatment in Germany. These comments take the recommendations of the Breast Committee of the Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie; AGO) into account. The report and assessment presented here pertain to the preliminary results of the ABC5 consensus. The final version of the statements will be published in Annals of Oncology and The Breast. [ABSTRACT FROM AUTHOR]

The 2015 St. Gallen Consensus Conference on early breast cancer took place in Vienna, Austria, for the first time. After 3 days of high-level presentations by international panel members of clinical trials having been reported recently in the field, the traditional Saturday voting tried to translate the assembled knowledge into clinical treatment recommendations intended to guide clinical practice of breast cancer care for the 'average' patient. This report summarizes the results of the 2015 international panel voting procedures with respect to locoregional and endocrine treatment, chemotherapy, targeted therapy, as well as adjuvant bisphosphonate use. This report is not aimed to replace the official St. Gallen consensus publication - some recommendations may even be altered in the final paper - but should serve as a preliminary rapid report of this important meeting. © 2015 S. Karger GmbH, Freiburg [ABSTRACT FROM AUTHOR]

The 2013 St. Gallen Consensus Conference on early breast cancer provided mostly evidence-based, globally valid treatment recommendations for breast cancer care, with a broad spectrum of acceptable clinical practice. This report summarizes the results of the 2013 international panel voting procedures with regard to loco-regional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use. This report is not aimed to replace the official St. Gallen Consensus publication, some recommendations may even be altered in the final paper, but should serve a preliminary rapid report of this important meeting. Copyright © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Information on several papers discussed at the 4th "COMBATing Breast Cancer Conference" 2011 held November 18-19, 2011 in Munich, Germany on the "Molecular Basics and Therapeutic Implications in Breast Cancer" is presented. Topic of discussion included the newest developments in basic, translational and clinical research focusing on targeted therapy and predictive markers. The conference was chaired by Nadia Harbeck, Manfred Kauffmann and Achim Rody.

The article discusses a roundatable discussion during the San Antonio Breast Cancer Symposium 2015, and mention topics including prognostic markers for breast cancer, clinical practices, and endocrine therapy.

No abstract available [ABSTRACT FROM AUTHOR]

Information about the 8th European Breast Cancer Conference (EBCC-8), held in Vienna, from March 21-24, 2012 is presented. The conference focused on the latest developments in breast cancer research and treatments. Some of the topics discussed included new application method of trastuzumab; intraoperative ultrasound to optimize breast conserving surgery; and overcoming hormone resistance. Also presented were updates on various trials in progress.

The article highlights several questions and answers from a discussion at the San Antonio Breast Cancer Symposium 2011. Some of the topics discussed include risk assessment tools used in the common histopathological and clinical criteria, most relevant clinical proceedings regarding HER2-positive breast cancer and m-Tor inhibitor as the next targeted therapy in breast cancer.

No abstract available [ABSTRACT FROM AUTHOR]